Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m fanolesomab

Drug Profile

Tc 99m fanolesomab

Alternative Names: Anti-CD15 IgM monoclonal antobody Tc 99m; Fanolesomab-Tc 99m; LeuTech; NeutroSpec; Tc 99m-anti-SSEA-1; Tc 99m-RB5 IgM; Technetium 99m-labeled mouse anti-CD-15 IgM monoclonal antibody

Latest Information Update: 21 Dec 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palatin Technologies; Wistar Institute
  • Class Heavy metals; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Infections

Most Recent Events

  • 19 Dec 2005 Withdrawn for Infection diagnosis in USA (IV)
  • 05 Dec 2005 Palatin and Tyco Healthcare communicated to healthcare providers several reports in patients with severe cardiopulmonary co-morbidities who experienced life-threatening or fatal reactions after administration of Tc 99m fanolesomab
  • 31 Aug 2004 Launched for Infection diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top